The expression of human telomerase reverse transcriptase (hTERT) is present in most malignant cells (.85%) but is undetectable in most normal somatic cells. Visualization of hTERT expression using radionuclide targeting can provide important diagnostic information in malignant tumors. The overall aim of this study was to evaluate whether 99m Tc-radiolabeled antisense oligonucleotide (ASON) targeting hTERT messenger RNA (mRNA) can be used for imaging of hTERT expression in vivo. Methods: One 18-mer antisense or sense uniformly phosphorothioate-modified oligonucleotide targeting hTERT mRNA was radiolabeled with 99m Tc through the bifunctional chelator N-hydroxysuccinimidyl derivative of S-acetylmercaptoacetyltriglycine (S-acetyl NHS-MAG3). Then the radiolabeled probe was characterized in vitro. Reverse transcription-polymerase chain reaction (RT-PCR) was performed to assay the mRNA level after proliferating cells had been incubated with the antisense and sense probes. 99m Tc-MAG3-ASON or 99m Tc-MAG3-SON was injected intravenously in mammary tumor-bearing BALB/c nude mice. Biodistribution and in vivo imaging was performed periodically. All data were analyzed by statistical software. Results: The labeling efficiencies of 99m Tc-MAG3-ASON/SON reached 76% 6 5% (n 5 5) within 15-30 min at room temperature, the specific activity was up to 1,850 kBq/mg, and the radiochemical purity was .96% after purification. 99m Tc-MAG3-ASON showed complete stability at room temperature and in fresh 37°C human serum. In comparison with 99m Tc-MAG3-SON, 99m Tc-MAG3-ASON preserved the capacity to bind living hTERT-expressing cells specifically and to inhibit the expression of hTERT mRNA significantly as well as ASON. In nude mice bearing hTERT-expressing MCF-7 xenografts, tumor radioactivity uptake of 99m Tc-MAG3-ASON after injection was significantly higher than that of 99m Tc-MAG3-SON after injection (P , 0.05). The hTERT-expressing xenografts were clearly imaged at 4-8 h noninvasively after injection of 99m Tc-MAG3-ASON, whereas the xenografts were not imaged at any time after injection of 99m Tc-MAG3-SON. Conclusion: This in vivo study provides evidence that 99m Tc-MAG3-ASON targeting hTERT mRNA can be used as a potential candidate for visualization of hTERT expression in carcinomas.
Tel omerase, a hallmark of malignant tumors, is minimally composed of the telomerase RNA (hTR), the telomerase reverse transcriptase (hTERT), and telomerase-associated proteins (1, 2) . hTERT represents the major determinant of telomerase activity. In contrast to hTR, which is commonly expressed in both normal tissues (without telomerase activity) and cancers, hTERT expression is found solely in tumor cells. Consequently, hTERT is one of the most attractive molecular markers available, promising a target spectrum of approximately 85% of all tumors (3, 4) . In addition, hTERT expression enhances the chemoresistance of cancer cells, and effective therapies are associated with decreased expression of hTERT, so imaging of hTERT expression also has prognostic value (5, 6) .
Although it has potential clinical significance, the measurement of hTERT expression has predominantly been by immunohistochemistry or by reverse transcription-polymerase chain reaction (RT-PCR), which requires the destruction of the tissues or cells examined. At present, reporter genes have provided new methods for noninvasive imaging, combining molecular biology with techniques such as fluorescent imaging, bioluminescent imaging, and radionuclide imaging. This indirect imaging paradigm usually includes a ''marker/ reporter gene'', a ''marker/reporter probe,'' and imaging technology that can visualize the spatial distribution of a probe (7, 8) . Examples using radionuclide or trimodality fusion imaging of hTERT promoter activity were recently published, and the results were encouraging (9, 10) .
However, direct inhibition of telomerase activity in cancer cells, a significant strategy, has been proposed. Compared with indirect imaging, imaging endogenous expression directly is more important, despite its greater difficulty, because it is directed at the genotypic basis of the normal phenotypic function of cells and at the alterations at gene expression that can initiate disease (11) . Thus, antisense imaging is one of the most promising tools of molecular imaging, whose strategies exploit the exquisite specificity of nucleic acid base-pair binding. Although there is much controversy, the use of antisense imaging as an in vivo diagnostic method is still attractive in that it would bring molecular imaging to the level of gene expression, especially for the early detection of tumor.
In present study, we tried to use antisense oligonucleotide (ASON) to noninvasively measure hTERT messenger RNA (mRNA) expression directly. One 18-mer antisense uniformly phosphorothioate-modified oligonucleotide targeting hTERT mRNA was radiolabeled with 99m Tc. We evaluated the characteristics of this antisense probe in vitro and observed whether it could be used for imaging of hTERT expression in malignant tumors in vivo.
MATERIALS AND METHODS
All oligonucleotides were purchased from the same source as the uniform phosphorothioates (Sangon Biotechnologies), purified with polyacrylamide gel electrophoresis (PAGE), and used as supplied. The sequence of ASON is 59-TAGAGACGTGGCTCT-TGA-39, and that of sense oligonucleotide (SON) is 59-TCAAG-AGCCACGTCTCTA-39, both with a primary amine on the terminal 39 phosphate group via a 6-member methylene carbon spacer, which was designed for covalent conjugation with the chelator. The molecular weight of chain was about 5.5 kDa each. The amine ASON/SON was generally handled under sterile conditions. The chelator of the N-hydroxysuccinimidyl derivative of S-acetylmercaptoacetyltriglycine (S-acetyl NHS-MAG3) was kindly provided by Donald J. Hnatowich (University of Massachusetts Medical School). Sephadex G25 (Amersham) was purchased and used as received. All other chemicals were reagent grade and were used without purification. The fresh 99m Tcpertechnetate generator eluate was obtained from a 99 Mo-99m Tc radionuclide generator (China Institute of Atomic Energy).
Oligonucleotide Conjugation and Radiolabeling
ASON with a primary amine on the terminal 39 phosphate group was conjugated with S-acetyl NHS-MAG3 as described (12, 13) . In brief, a solution of ASON was prepared at a concentration of 5 mg/mL in 0.1 M N-(2-hydroxyethyl)piperazine-N9-(2-ethanesulfonic acid) (HEPES) buffer, pH 8.0. A fresh 20 mg/mL solution of S-acetyl-NHS-MAG3 in dry N,N-dimethylformamide (DMF) was added dropwise with agitation to a final MAG3-to-ASON molar ratio of 20:1. This reaction mixture was incubated at room temperature for 60-120 min. Then the conjugated ASON was purified on a 0.7 · 20 cm Sephadex G25 gel-filtration column using sterile 50 mM phosphate buffer, pH 7.2, as eluant. The peak fractions were pooled, and the DNA concentration was quantitated by a recording ultraviolet visible spectrophotometer (SMA3000; Beijing Genomics Institute, China) at 260 nm (optical density, 33 mg/mL). The preparation of MAG3-ASON was dispensed at 10 mg per vial, lyophilized, and stored at 220°C for future use. SON was treated as described for ASON.
A fresh 50 mg/mL solution of sodium tartrate was prepared in sterile 0.5 M sodium bicarbonate, 0.25 M ammonium acetate, 0.175 M ammonium hydroxide, pH 9.2. The high pH of the tartrate solution was necessary so that the final pH would be approximately 7.6. In addition, a 1 mg/mL solution of SnCl 2 Á2H 2 O in 10 mM hydrochloric acid was prepared just before use. At room temperature, the conjugated and purified MAG3-ASON (10 mg) was typically dissolved at a concentration of 500 mg/mL in 0.25 M ammonium acetate buffer, pH 5.2. To the solution of MAG3-ASON, sodium tartrate was added as a transchelator to a final concentration of about 7 mg/mL, and the labeling pH reached 7.6. Then sufficient 99m Tc-pertechnetate generator eluate (10 mL) was added to this solution to provide about 3,700 kBq/mg of ASON. The stannous ion solution was added immediately thereafter such that 1 mg of SnCl 2 Á2H 2 O was added for each 10 mg of ASON. After 15-30 min, the labeled MAG3-ASON preparation was purified on a 0.7 · 20 cm Sephadex G25 gel-filtration column with 50 mM phosphate buffer, pH 7.2, eluant. Fractions were collected to detect the radioactivity and absorbance at 260 nm. SON was radiolabeled identically with 99m Tc.
For routine quality control of labeling, the labeling efficiency and radiochemical purity of radiolabeled probes were calculated by paper chromatography on Xinhua no. 1 filter paper with acetone and normal saline as the mobile phase.
In Vitro Stability Analysis
To evaluate the labeling stability, the radiochemical purity of 99m Tc-MAG3-ASON at room temperature, as well as that in normal saline at room temperature and in fresh 37°C human serum at 0.01 mg/mL, was confirmed by paper chromatography periodically over 24 h.
PAGE was performed to assess the stability of 99m Tc-MAG3-ASON in serum by comparing the electrophoretic mobility. Incubation with fresh 37°C human serum for 1, 2, 4, and 6 h later, 99m Tc-MAG3-ASON was extracted by a phenol/chloroform method. After ethanol precipitation at 220°C overnight, the samples were centrifugated (12,000g/min) for 10 min. The precipitation was dried naturally and redissolved in distilled water. Then the samples in each time point, including the control, were resolved on 20% PAGE and stained with silver nitrate. The resulting gels were finally scanned using an ultraviolet transilluminator (AlphaImager 2200; Alpha Innotech Corp.) and photographed.
Cell Culture
The HepG2 cell line was a generous gift from the Department of Infectious Disease, Peking University First Hospital, and was maintained in the media recommended by them. The cells were grown in Dulbecco's modified Eagle medium (DMEM) containing L-glutamine (2 mM), sodium bicarbonate (1.5 mg/L), nonessential amino acids (0.1 mM), and sodium pyruvate (1.2 mM), supplemented with 10% fetal bovine serum (FBS) and 100 mg/mL of penicillin-streptomycin (GIBCO). Cells were cultivated under standard conditions (37°C, humidified atmosphere containing 5% CO 2 ). Cells between passages 4 and 12 were used and were harvested by trypsin treatment (0.25% trypsin/0.02% ethylenediaminetetraacetic acid, 5 min, 37°C). The cell growth status was monitored by inverted microscopy with phase contrast, and cell viability was assessed by trypan blue exclusion.
Cell Transfections
Before transfection, the cells were seeded in appropriate culture plates and grown for 2 d. On the third day, the cells were jnm042622-twp n 11/9/07 transfected once, with a mixture consisting of molecular probe and liposome (ratio, 1:3 w/w, diluted in serum-free OptiMEM) according to the manufacturer's instructions (Lipofectamine 2000; Invitrogen). After incubation under standard conditions for 4 h, the cells were washed with phosphate-buffered saline (PBS) and incubated in fresh culture medium (DMEM with 10% FBS) to maintain growth, until additional analyses.
RT-PCR
After transfection with 99m Tc-MAG3-ASON, 99m Tc-MAG3-SON, and ASON, respectively, the cells were trypsinized and washed twice with PBS. The total cellular RNA was extracted from the HepG2 cells by Trizol 1-step method (TRIZOL reagent; Bio Basic Inc.). For reverse transcription, 2 mg of total RNA were subjected to reverse transcription primed by oligodeoxythymidine with avian myeloblastosis virus reverse transcriptase according to the recommendations of the First Strand cDNA Synthesis Kit (Bio Basic Inc.). Then the complementary DNA (cDNA) was applied to perform PCR using the PCR Kit (Sangon Biotechnologies). As an internal control for cDNA synthesis, the housekeeping gene of b-actin was amplified too. PCR primers were as follows:
hTERT: ðleft primerÞ 59-TCTACCGGAAGAGTGTCTGGAGCAA-39 ðright primerÞ 59-GCTCCCACGACGTAGTCCATGTTCA-39
202-bp predicted product size:
b-Actin: ðleft primerÞ 59-GTGGGGCGCCCCAGGCACCA-39 ðright primerÞ 59-GTCCTTAATGTCACGCACGATTTC-39 540-bp predicted product size:
PCR amplification of hTERT cDNA was performed with an initial heating at 94°C for 4 min, followed by 34 cycles consisting of denaturing for 30 s at 94°C, annealing for 30 s at 61°C, and elongation for 30 s at 72°C, and a final extension period of 5 min at 72°C. PCR amplification of b-actin was performed as described. Amplified products were size-fractionated by 2% agarose gel electrophoresis. The gel was stained with ethidium bromide (1 mg/mL), visualized by an ultraviolet transilluminator, and photographed. The density of each PCR band was measured and analyzed by video documentation system software (AlphaImager version 5.5; Alpha Innotech Corp.). The amount of mRNA products for hTERT was expressed as the ratio to b-actin mRNA product, which was conserved as the internal control.
Biodistribution of 99m Tc-MAG3-ASON and 99m Tc-MAG3-SON in MCF-7 Xenograft-Bearing Nude Mice After Systemic Injection BALB/c nu/nu mice (female, 20 6 3 g, 4-to 6-wk-old; Department of Laboratory Animal Science, Peking University Health Science Center) were used in this study. The mice were inoculated with 1 · 10 7 MCF-7 mammary tumor cells (obtained from Department of Laboratory Animal Science, Peking University Health Science Center) in the right upper limbs, and the tumors were allowed to grow to a diameter of 1.0 cm. The mice were maintained using a standard diet, bedding, and environment, with free access to food and drinking water.
Fifty BALB/c nu/nu mice with MCF-7 xenografts were randomly divided into 10 groups of 5 mice each (5 groups for injection of antisense probe, another 5 groups for injection of sense probe). Immediately after Sephadex G25 gel-filtration column purification, 1 mg (1,850 kBq) of 99m Tc-MAG3-ASON (or 99m Tc-MAG3-SON) in 100 mL of eluant (50 mM phosphate buffer, pH 7.2) was injected into each mouse via a tail vein. All injections were tolerated well. At 0.5, 1, 2, 4, and 6 h after injection, the mice were sacrificed by cervical dislocation. Then the mice were dissected and tissues of interest (heart, liver, spleen, lung, kidney, stomach, small intestine, bladder, skeletal muscle, bone marrow, blood, and tumor) were weighed, and their radioactivity was measured using a g-well counter along with a standard of the injection. Radioactivity results were recorded as the percentage injected activity per gram (%ID/g) of tissue corrected for background and decay.
g-Camera Imaging
Ten BALB/c nu/nu mice with MCF-7 xenografts were randomly divided into 2 groups of 5 mice each (one group for injection of antisense probe, the other for injection of sense probe). Immediately after Sephadex G25 gel-filtration column purification, 4 mg (7,400 kBq) of the antisense or sense probe in 100 mL of eluant (50 mM phosphate buffer, pH 7.2) were injected into each mouse via a tail vein. All injections were tolerated well. At 0.5, 1, 2, 4, 6, and 8 h after injection, imaging was performed in the Department of Nuclear Medicine, Peking University First Hospital, using SPECT (SPR SPECT; GE Healthcare, Inc.) equipped with a low-energy, high-resolution, parallel-hole collimator. Static images (100,000 counts), obtained with a zoom factor of 2.0, were digitally stored in a 256 · 256 matrix.
Statistical Analysis
The variables are expressed as average 6 SD ( x 6 SD). The variables of RT-PCR were analyzed using 1-way ANOVA, and other statistical comparisons of average values were performed with the Student t test. P , 0.05 was considered significant.
RESULTS

Oligonucleotide Conjugation and Radiolabeling
Under the set of conditions, average labeling efficiencies of 76% 6 5% (n 5 5) were achieved within 15-30 min at room temperature, specific activities of up to 1,850 kBq/mg were obtained, and radiochemical purity was .96% after purification. Control labeling of unmodified ASON under the same conditions showed only about 5% 6 1.6% (n 5 5) binding, indicating that radiolabeling was largely specific and mediated by the chelator.
The labeling efficiency and radiochemical purity of radiolabeled agent were calculated by the paper chromatography on Xinhua no. 1 filter paper with acetone and normal saline as the mobile phase. With acetone as the mobile phase, only 99m Tc-pertechnetate migrated with the solvent, whereas 99m Tc-MAG3-ASON and other labeled colloids remained at the origin. Otherwise, with the normal saline as the mobile phase, 99m Tc-pertechnetate and 99m Tc-MAG3-ASON migrated with the solvent, whereas labeled colloids remained at the origin ( ½Table 1  Table 1 ).
In Vitro Stability Analysis
The radiochemical purity of 99m Tc-MAG3-ASON under dif ½Fig: 1 -ferent conditions was .93% periodically over 24 h (Fig. 1). jnm042622-twp n 11/9/07
It is very important for radiolabeled ASON to retain stability when considered for the application in imaging in vivo. PAGE can differentiate even 1 base change of oligonucleotide, so it is a highly sensitive method for detecting the probability of degradation of ASON. PAGE showed that radiolabeled probe remained stable in fresh 37°C human serum ( ½Fig: 2 Fig. 2 ).
RT-PCR
A significant decrease of hTERT mRNA expression was observed in cells treated with 99m Tc-MAG3-ASON and ASON compared with that in cells treated with 99m Tc-MAG3-SON and 10% FBS (P , 0.05, n 5 3). However, there were no significant differences of hTERT mRNA expression between the cells treated with 99m Tc-MAG3-SON and 10% FBS and between the cells treated with 99m Tc-MAG3-ASON and ASON ( ½Fig: 3 Fig. 3 ). Biodistribution data are shown in ½Table 2 Tables 2 and 3 . At a different time ½Table 3 phase after injection of 99m Tc-MAG3-ASON, the probe accumulated primarily in the kidney and liver, followed by the stomach and tumor. None of the other organs (and tissues) investigated showed high uptake of radiolabeled ASON. A high renal radioactivity accumulation indicated that the substance was cleared primarily through the urinary system. In addition, the biodistribution of 99m Tc-MAG3-ASON was characterized by quick blood clearance, with 2.62 6 0.167 %ID/g remaining 0.5 h after injection and 1.051 6 0.121 %ID/g remaining at 2 h. The biodistribution of 99m Tc-MAG3-SON shared similar characteristics with 99m Tc-MAG3-ASON, except the radioactivity uptake in tumor.
In comparison with radioactivity concentration in the tumor after injection of 99m Tc-MAG3-ASON, that after injection of 99m Tc-MAG3-SON was significantly lower (P , 0.05) ( ½Fig: 4 Fig. 4 ). Due to blood clearance, the tumor uptake of 99m Tc-MAG3-SON was gradually decreasing. However, the tumor uptake of 99m Tc-MAG3-ASON increased after 2 h and remained at the relatively high level until the 6-h time point after injection. As a result, the tumor-to-nontumor (T/NT) accumulation ratio after injection of 99m Tc-MAG3-ASON was significantly higher than that after injection of 99m Tc-MAG3-SON, especially after 4 h ( ½Fig: 5 Fig. 5 ). After injection of 99m Tc-MAG3-ASON, the tumor-to-muscle (T/M) ratio exceeded 8.8, and the tumor-to-blood (T/B) ratio reached 2.0 at 6 h.
g-Camera Imaging
In nude mice bearing hTERT-expressing MCF-7 xenografts, the tumors were clearly imaged at 4-8 h noninvasively after the administration of 99m Tc-MAG3-ASON. On the contrary, the tumors were not imaged at any time after injection of 99m Tc-MAG3-SON ( ½Fig: 6 Fig. 6 ). As predicted from the biodistribution studies, the renal route of elimination of the probes also led to substantial radioactivity accumulation in the abdomen. jnm042622-twp n 11/9/07
DISCUSSION
The induction of hTERT expression results in telomerase activity and contributes, as part of a multistep process, to human carcinogenesis. Most malignant tumors (.85%) show hTERT activity. Therefore, targeting the catalytic subunit hTERT represents a promising approach for providing diagnostic value in several types of cancer, and it will probably not cause substantial side effects on telomerase-negative, somatic cells (14) (15) (16) . Until recently, the measurement of hTERT expression required the destruction of the tissues or cells under investigation, such as immunohistochemistry or PCR. There are also some reports about nondestructive methods of measuring hTERT expression using reporter gene imaging, in which hTERT serves as a promoter. Because the detection of hTERT expression has potential clinical significance, we attempt to use antisense imaging to measure hTERT expression in vivo directly.
Antisense imaging, a specific and noninvasive technology, is based on the complementarity of the constructs to the appropriate target mRNA. Pioneering work in this field was reported by Dewanjee MK et al. in 1994 , who used a 15-mer phosphorothioate antisense oligodeoxyribonucleotide labeled with 111 In to image constitutive c-myc gene expression in a murine mammary carcinoma model (17) . Up to now, ASONs targeting c-MYC, P-glycoprotein (Pgp), CCND1, mdr1, bcl-2, k-ras, unr, IgV H FR1 mRNA, and so forth have been chosen to be labeled with radionuclides such as 99m Tc, 111 In, 68 Ga, 64 Cu, 131 I and so forth (18) (19) (20) (21) (22) (23) (24) (25) (26) , whose results all facilitate the development of antisense imaging. Despite an extensive literature search, we failed to find any research publication describing in vivo imaging of hTERT expression by antisense technology. In the present study, we used radiolabeled ASON targeting hTERT mRNA to measure hTERT expression in malignant tumors in vivo.
The choice of an efficient ASON targeting hTERT mRNA is critical. One of the limiting factors, discriminating between efficient and ineffective ASONs, is the accessibility of the target RNA sequence, because stable secondary structures might prevent ASON hybridization. Experimental (''walk the gene,'' ribonuclease H mapping), as well as theoretic, procedures (secondary structure prediction of the RNA) should increase the probability of finding effective antisense molecules (27, 28) . Another key factor is the optimum length that the ASON needs to bind to its target. According to statistical calculations, the jnm042622-twp n 11/9/07 optimum size should be between 15 and 20 bases for a given oligonucleotide to meet only 1 target in the human genome (29) . On the basis of the principles of ASON design and previous study (30) , the ASON of 59-TAGAGACGT-GGCTCTTGA-39, which is complementary to the hTERT mRNA (4,015 nucleotides; accession no. AF015950), was chosen. BLAST (Basic Local Alignment Search Tool) database searches performed for ASON revealed no complementary sequences to mRNAs (except for hTERT mRNA). Considering several important reasons-such as the good imaging characteristics, facile logistics of delivery, wellstudied labeling chemistry, ready availability, and even potentially clinical practice-we directed our efforts toward developing a 99m Tc-labeled probe for single-photon detection. Because 99m Tc is a g-emitting metal, radiolabeling is usually accomplished by chelation to exogenous chelators previously conjugated to the oligonucleotides. As a result, the labeling efficiency of 99m Tc-labeled MAG3-ASON/ SON was .75%, the radiochemistry purity after purification was up to 96%, and the specific activities were 1,850 kBq/mg. In addition, 99m Tc-MAG3-ASON showed stability and completeness at room temperature and in fresh 37°C human serum. These characteristics of 99m Tc-MAG3-ASON showed that this radiolabeled probe was suitable for the purpose of imaging in vivo.
One major problem of antisense technology is to improve the stability of oligonucleotides. To date, 3 generations of chemically modified oligonucleotides have been used, including phosphorothioate oligonucleotide, methylphosphonates, peptide nucleic acid (PNA), morpholino, and chimeric molecules (PNA/DNA-chimera). Although many analogs overcome the stability problem, the phosphorothioate modification, which has acceptable physical and chemical properties and shows reasonable resistance to nucleases, still represents the most widely used class of antisense compounds (31) . Several pharmaceuticals based on it have been in clinical application or under clinical trails. We used uniformly phosphorothioate-modified oligonucleotide in this study and proved its specificity and stability in vitro when radiolabeled with 99m Tc.
Another major obstacle for efficient antisense technology is the low internalization rate of oligonucleotides into target cells. There are no direct receptors in the cell membrane for oligonucleotides, so the uptake mechanism is nonspecific and relies on binding to cell-surface proteins or receptormediated adsorptive endocytosis or pinocytosis, which are known to be concentration and energy dependent (29, 32) . The other uptake mechanism is through a direct cellmembrane permeation process, which is more efficient (31) . Depending on the oligonucleotides, cell line, and experimental conditions, the cell uptake rate ranges from 1% to 20% (33) . Nowadays, transfection with liposomes, ligand-conjugated polyethyleneimine complex, and viralderived agents (particularly adenoviruses and retroviruses) jnm042622-twp n 11/9/07 have been applied in antisense technology (34) (35) (36) . In vitro, liposomes or viral vectors are required to efficiently transfect cells with phosphorothioate ASONs, but transfection does not seem necessary in vivo, as the inhibition of the expression of the target can be accomplished with ASONs alone (37) . Interestingly, in animal models and in patients, all therapeutically active ASONs have been administered in the form of naked compounds. It has been elucidated that in intact tissues other mechanisms exist, which can act in the same way as cationic carrier lipids (31) . In the present study, we introduced the probes into cells using liposome.
As for animal experiments, however, we injected the radiolabeled oligonucleotides directly. The results of RT-PCR showed that in comparison with 99m Tc-MAG3-SON, 99m Tc-MAG3-ASON could inhibit the expression of hTERT mRNA significantly as well as ASON. It was proven that the antisense probe hybridized to the sequence on the whole hTERT mRNA in cells specifically and decreased the expression of hTERT mRNA. A reduction of hTERT transcript number after anti-hTERT ASON treatment was also observed by Zhang and He in leukemic cell lines (16) and Kraemer et al. in human bladder cancer cell lines (30) .
The biodistribution of 99m Tc-MAG3-ASON (and 99m Tc-MAG3-SON) in mice bearing MCF-7 xenografts showed that the radiolabeled probes preferentially accumulated in the kidney and liver, and lesser accumulation was observed in the stomach, indicating the imaging agent was cleared primarily through the urinary system and digestion system. At any time points after injection, the accumulation of 99m Tc-MAG3-ASON in the tumor tissue was significantly higher than that of 99m Tc-MAG3-SON (P , 0.05). Furthermore, the accumulation of 99m Tc-MAG3-ASON in the tumor tissue increased gradually from 2 until 6 h after injection, whereas that of 99m Tc-MAG3-SON in tumor tissue decreased. We noted that the uptake curves between 2 and 6 h reflected the specific cellular retention, possibly related to the specific hybridization of the antisense probe on the targeted sequence. However, there was a relatively high uptake of 99m Tc-MAG3-ASON/SON at 30 min and 1 h, because at the early times after injection, the measured radioactivity reflected the transport of the probe (26) and corresponded to a nonspecific phenomenon. As for the different uptake of the 2 probes at 30 min and 1 h, we proposed that this was related to cell-membrane nonspecific binding, which could reasonably be different, for physicochemical reasons, for the 2 different molecules. In addition, the ratios of T/NT after injection of 99m Tc-MAG3-ASON were significantly higher than those after injection of 99m Tc-MAG3-SON. These results could support the mechanism of antisense-that is, the specific hybridization of jnm042622-twp n 11/9/07 99m Tc-MAG3-ASON to hTERT mRNA results in the specific accumulation of radiolabeled ASON in the hTERTexpressed tumors.
A differential antisense accumulation in ACHN tumor cells (a human renal adenocarcinoma cell type) was visualized with microautoradiography (12) , which demonstrated the intracellular localization of the tracers. As for in vivo imaging, further evidence concerning the reality of the intracellular localization of the tracers after intravenous injection should also be provided. For example, real-time PCR or immunohistochemistry can specifically measure the target mRNA or protein level after injection of antisense probe. Microautoradiography can find radioactivity inside cells if the specific retention really does correspond to the hybridization between antisense probe and targeted mRNA.
The results of imaging of hTERT expression in MCF-7 xenografts using the radiolabeled probes were consistent with the results of biodistribution. Tumors were clearly visualized after injection of 99m Tc-MAG3-ASON but were not clearly imaged after injection of 99m Tc-MAG3-SON. High uptake and retention in kidneys and liver is a general problem for radiometal-labeled oligonucleotides. This is also an apparent obstacle for imaging the tumors in these organs. However, this does not seem to be a problem for SPECT of hTERT expression in breast carcinomas in our study, where the tumor is anatomically well separated from the kidneys and liver.
All results of our study give a good reason that 99m Tc-MAG3-ASON targeting hTERT mRNA can be used for detection of hTERT expression in malignant tumors in vivo. However, improvements in tumor delivery and normal tissue clearance are needed for further study on antisense imaging.
CONCLUSION
The expression of hTERT, a critical cancer hallmark, can be measured by 99m Tc-MAG3-ASON targeting hTERT mRNA, which is a potential and promising candidate for visualization of hTERT expression in carcinomas.
